BMBenjamin James Miller

Benjamin James Miller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Benjamin James Miller has a total of 159 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Phase Ib/II Trial of Pharmacologic Ascorbate With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcoma of the Trunk and Extremities

    by Varun Monga, John Rieth, Benjamin Miller, Hisakazu Hoshi, Carlos Chan, Bryan Allen, Carryn Anderson, Kristen Plichta, Munir Tanas, Jonathan Davick, et al.

    PURPOSE: To evaluate the safety and preliminary efficacy of pharmacologic ascorbate combined with neoadjuvant radiation in patients with localized high-risk soft tissue sarcoma (STS). METHODS: This phase Ib/II trial enrolled 25 patients with histologically confirmed STS of the extremities, chest wall, and retroperitoneum. Patients received intravenous ascorbate (75 g) three times a week during standard preoperative radiotherapy (50 Gy in 25 Fx). Primary objectives of phase Ib included safety assessment, with the primary objective of phase II being pathologic complete response (pCR) rate defined as tumor necrosis ≥95%. Secondary end points assessed event-free survival (EFS) and overall survival (OS). Exploratory end points included postinfusion ascorbate and immunophenotyping flow cytometry from peripheral blood and tumors. RESULTS: Treatment grade 3-4 adverse events included lymphopenia (20%), anemia (4%), and hypertension (8%). No therapy-related deaths occurred. The phase II trial primary end point was not met, with three (12%) of 25 patients achieving pCR. Partial responses were observed in two, with 22 demonstrating stable disease. EFS at 12 and 24 months was 68% and 60%, whereas OS was 96% at 12 months and 80% at 24 months. Flow cytometry analysis revealed increases in activated effector CD8+ T cells compared with control subjects who underwent neoadjuvant radiation without the addition of pharmacologic ascorbate. The study also revealed positive correlations between changes in tumor-infiltrating lymphocytes and peripheral blood T-cell populations. CONCLUSION: Pharmacologic ascorbate plus neoadjuvant radiation demonstrated manageable safety but did not significantly improve primary end points. However, the observed correlations between peripheral blood and tumor T-cell changes provide valuable insights into potential immune mechanisms that could inform future combination strategies.


  • Open Access

    Lower Levels of TAZ Expression Associated with Post-Surgical Wound Healing Complications in Soft Tissue Sarcoma Patients Treated with Preoperative Radiation

    by Jacob D. Gylten, Jane E. Persons, Benjamin J. Miller, Qiang An, Munir R. Tanas, Stephanie J. T. Chen

    Background/Objectives: Pre-operative radiation (Pre-RT) decreases local recurrence following soft tissue sarcoma (STS) resection but carries the risk of wound healing complications (WHCs). This study evaluated skin specimens and clinical characteristics of STS patients to (1) compare patients with and without Pre-RT, (2) compare Pre-RT patients with and without WHCs, and (3) explore associations between clinical characteristics and WHCs. Methods: This retrospective study included 54 adults who underwent STS resection with primary closure (Pre-RT n = 30). A pathologist who was blinded to the clinical outcomes evaluated the skin specimens microscopically. Results: Irradiated skin had lower vessel density and was more likely to lack hair follicles and sebaceous glands, consistent with the effects of radiation. Irradiated skin was also more likely to include plasma cells. Irradiated skin demonstrated higher mean TAZ H-scores; however, within the Pre-RT subset, those patients who developed WHCs demonstrated comparatively lower TAZ. Conclusions: This novel finding may suggest that higher TAZ in irradiated skin reflects a response to injury but that comparatively lower TAZ in irradiated skin might contribute to WHCs. Future studies should consider more focused evaluation of TAZ in STS resections with Pre-RT as they may help to predict WHCs when used in combination with other histologic factors and could suggest a therapeutic target.


  • Open Access

    Superoxide Dismutase Mimetic Avasopasem Manganese Enhances Radiation Therapy Effectiveness in Soft Tissue Sarcomas and Accelerates Wound Healing

    by Amira Zaher, Kranti A. Mapuskar, Michael S. Petronek, Munir R. Tanas, Alexandra L. Isaacson, Rebecca D. Dodd, Mohammed Milhem, Muhammad Furqan, Douglas R. Spitz, Benjamin J. Miller, et al.

    Soft tissue sarcomas (STSs) are mesenchymal malignant lesions that develop in soft tissues. Despite current treatments, including radiation therapy (RT) and surgery, STSs can be associated with poor patient outcomes and metastatic recurrences. Neoadjuvant radiation therapy (nRT), while effective, is often accompanied by severe postoperative wound healing complications due to damage to the surrounding normal tissues. Thus, there is a need to develop therapeutic approaches to reduce nRT toxicities. Avasopasem manganese (AVA) is a selective superoxide dismutase mimetic that protects against IR-induced oral mucositis and lung fibrosis. We tested the efficacy of AVA in enhancing RT in STSs and in promoting wound healing. Using colony formation assays and alkaline comet assays, we report that AVA selectively enhanced the STS (liposarcoma, fibrosarcoma, leiomyosarcoma, and MPNST) cellular response to radiation compared to normal dermal fibroblasts (NDFs). AVA is believed to selectively enhance radiation therapy by targeting differential hydrogen peroxide clearance in tumor cells compared to non-malignant cells. STS cells demonstrated increased catalase protein levels and activity compared to normal fibroblasts. Additionally, NDFs showed significantly higher levels of GPx1 activity compared to STSs. The depletion of glutathione using buthionine sulfoximine (BSO) sensitized the NDF cells to AVA, suggesting that GPx1 may, in part, facilitate the selective toxicity of AVA. Finally, AVA significantly accelerated wound closure in a murine model of wound healing post RT. Our data suggest that AVA may be a promising combination strategy for nRT therapy in STSs.


  • The Influence of Hospital Characteristics on Patient Survival in Surgically Managed Metastatic Disease of Bone

    by Emma L. Herbach, Bradley D. McDowell, Elizabeth A. Chrischilles, Benjamin J. Miller

    Objectives: We investigated whether patients receiving surgical treatment for metastatic disease of bone (MDB) at hospitals with higher volume, medical school affiliation, or Commission on Cancer accreditation have superior outcomes. Materials and Methods: Using the Surveillance, Epidemiology, and End Results–Medicare database, we identified 9413 patients surgically treated for extremity MDB between 1992 and 2014 at the age of 66 years or older. Cox proportional hazards models were used to calculate the hazards ratios (HR) for 90-day and 1-year mortality and 30-day readmission according to the characteristics of the hospital where bone surgery was performed. Results: We observed no notable differences in 90-day mortality, 1-year mortality, or 30-day readmission associated with hospital volume. Major medical school affiliation was associated with lower 90-day (HR: 0.88, 95% confidence interval [CI]: 0.80-0.96) and 1-year (HR: 0.92, 95% CI: 0.87-0.99) mortality after adjustments for demographic and tumor characteristics. Surgical treatment at Commission on Cancer accredited hospitals was associated with significantly higher risk of death at 90 days and 1 year after the surgery. This effect appeared to be driven by lung cancer patients (1-year HR: 1.17, 95% CI: 1.07-1.27). Conclusions: Our findings suggest surgical management of MDB at lower-volume hospitals does not compromise survival or readmissions. There may be benefit to referral or consultation with an academic medical center in some tumor types or clinical scenarios.


  • Transcutaneous Oximetry Does Not Reliably Predict Wound-healing Complications in Preoperatively Radiated Soft Tissue Sarcoma

    by Lukas M. Nystrom, Nathan W. Mesko, Yuxuan Jin, Chirag Shah, Andre Spiguel, Jeremy White, Benjamin J. Miller

    Background: Surgical wound-healing complications after tumor resections in tissue that has been preoperatively radiated are a major clinical problem. Most studies have reported that complications occur in more than 30% of patients undergoing such resections in the lower extremity. There is currently no available method to predict which patients are likely to have a complication. Transcutaneous oximetry has been identified in preliminary studies as potentially useful, but the available evidence on its efficacy for this application thus far is inconclusive. Questions/purposes: (1) Does transcutaneous oximetry measurement below 25 mmHg at any location in the surgical wound bed predict a wound-healing complication? (2) Does recovery (increase) in transcutaneous oxygen measurement during the rest period between the end of radiation and the time of surgery protect against wound-healing complications? Methods: A prospective, multi-institution study was coordinated to measure skin oxygenation at three timepoints in patients undergoing surgery for a lower extremity soft tissue sarcoma after preoperative radiation. Between 2016 and 2020, the five participating centers treated 476 patients for lower extremity soft tissue sarcoma. Of those, we considered those with a first-time sarcoma treated with radiation before limb salvage surgery as potentially eligible. Based on that, 21% (98 of 476) were eligible; a further 12% (56 of 476) were excluded because they refused to participate or ultimately, they were treated with a flap, amputation, or skin graft. Another 1% (3 of 476) of patients were lost because of incomplete datasets or follow-up less than 6 months, leaving 8% (39 of 476) for analysis here. The mean patient age was 62 ± 14 years, 62% (24 of 39) of the group were men, and 18% (7 of 39) of patients smoked cigarettes; 87% (34 of 39) of tumors were intermediate/high grade, and the most common histologic subtype was undifferentiated pleomorphic sarcoma. In investigating complications, a cutoff of 25 mmHg was chosen based on a pilot investigation that identified this value. All patients were assessed for surgical wound-healing complications, which were defined as: those resulting in a return to the operating room, initiation of oral or IV antibiotics, intervention for seroma, or prolonged wound packing or dressing changes. To answer the first research question, we compared the proportion of patients who developed a wound-healing complication between those patients who had any reading below 25 mmHg (7 of 39) and those who did not (32 of 39). To answer the second question, we compared the group with stable or decreased skin oxygenation (22 of 37 patient measurements [two patients missed the immediate postoperative measurement]) to the group that had increased skin oxygen measurement (15 of 37 measurements) during the period between the end of radiation and the surgical procedure; again, the endpoint was the development of a wound-healing complication. This study was powered a priori to detect an unadjusted odds ratio for wound-healing complications as small as 0.71 for a five-unit (5 mmHg) increase in TcO2 between the groups, with α set to 0.05, β set to 0.2, and a sample size of 40 patients. Results: We found no difference in the odds of a wound-healing complication between patients whose transcutaneous oxygen measurements were greater than or equal to 25 mmHg at all timepoints compared with those who had one or more readings below that threshold (odds ratio 0.27 [95% confidence interval (CI) 0.05 to 1.63]; p = 0.15). There was no difference in the odds of a wound-healing complication between patients who had recovery of skin oxygenation between radiation and surgery and those who did not (OR 0.63 [95% CI 0.37 to 5.12]; p = 0.64). Conclusion: Transcutaneous oximetry cannot be considered a reliable test in isolation to predict wound-healing complications. This may be a function of the fact that transcutaneous oximetry samples a relatively small portion of the landscape in which a wound-healing complication could potentially arise. In the absence of a reliable diagnostic test, clinicians must still use their best judgment regarding surgical timing and work to address modifiable risk factors to avoid complications. The unanswered question that remains is whether there is a skin perfusion or oxygenation issue at the root of these complications, which seems likely. Alternative approaches that can assess the wound more broadly and in real time, such as fluorescent probes, may be deserving of further investigation. Level of Evidence: Level II, diagnostic study.


  • Open Access

    Web-Based Patient Educational Material on Osteosarcoma: Quantitative Assessment of Readability and Understandability

    by Trevor Robert Gulbrandsen, Mary Kate Skalitzky, Alan Gregory Shamrock, Burke Gao, Obada Hasan, Benjamin James Miller

    Background: Patients often turn to web-based resources following the diagnosis of osteosarcoma. To be fully understood by average American adults, the American Medical Association (AMA) and National Institutes of Health (NIH) recommend web-based health information to be written at a 6th grade level or lower. Previous analyses of osteosarcoma resources have not measured whether text is written such that readers can process key information (understandability) or identify available actions to take (actionability). The Patient Education Materials Assessment Tool (PEMAT) is a validated measurement of understandability and actionability. Objective: The purpose of this study was to evaluate web-based osteosarcoma resources using measures of readability, understandability, and actionability. Methods: Using the search term “osteosarcoma,” two independent Google searches were performed on March 7, 2020 (by AGS), and March 11, 2020 (by TRG). The top 50 results were collected. Websites were included if they were directed at providing patient education on osteosarcoma. Readability was quantified using validated algorithms: Flesh-Kincaid Grade Ease (FKGE), Flesch-Kincaid Grade-Level (FKGL). A higher FKGE score indicates that the material is easier to read. All other readability scores represent the US school grade level. Two independent PEMAT assessments were performed with independent scores assigned for both understandability and actionability. A PEMAT score of 70% or below is considered poorly understandable or poorly actionable. Statistical significance was defined as P≤.05. Results: Two searches yielded 53 unique websites, of which 37 (70%) met the inclusion criteria. The mean FKGE and FKGL scores were 40.8 (SD 13.6) and 12.0 (SD 2.4), respectively. No website scored within the acceptable NIH or AHA recommended reading level. Only 4 (11%) and 1 (3%) website met the acceptable understandability and actionability threshold. Both understandability and actionability were positively correlated with FKGE (ρ=0.55, P<.001; ρ=0.60, P<.001), but were otherwise not significantly associated with other readability scores. There were no associations between readability (P=.15), understandability (P=.20), or actionability (P=.31) scores and Google rank. Conclusions: Overall, web-based osteosarcoma patient educational materials scored poorly with respect to readability, understandability, and actionability. None of the web-based resources scored at the recommended reading level. Only 4 achieved the appropriate score to be considered understandable by the general public. Authors of patient resources should incorporate PEMAT and readability criteria to improve web-based resources to support patient understanding.


  • The preoperative machine learning algorithm for extremity metastatic disease can predict 90‐day and 1‐year survival: An external validation study

    by Mary Kate Skalitzky, Trevor R. Gulbrandsen, Olivier Q. Groot, Aditya V. Karhade, Jorrit‐Jan Verlaan, Joseph H. Schwab, Benjamin J. Miller

    Background: The prediction of survival is valuable to optimize treatment of metastatic long‐bone disease. The Skeletal Oncology Research Group (SORG) machine‐learning (ML) algorithm has been previously developed and internally validated. The purpose of this study was to determine if the SORG ML algorithm accurately predicts 90‐day and 1‐year survival in an external metastatic long‐bone disease patient cohort.Methods: A retrospective review of 264 patients who underwent surgery for long‐bone metastases between 2003 and 2019 was performed. Variables used in the stochastic gradient boosting SORG algorithm were age, sex, primary tumor type, visceral/brain metastases, systemic therapy, and 10 preoperative laboratory values. Model performance was calculated by discrimination, calibration, and overall performance.Results: The SORG ML algorithms retained good discriminative ability (area under the cure [AUC]: 0.83; 95% confidence interval [CI]: 0.76–0.88 for 90‐day mortality and AUC: 0.84; 95% CI: 0.79–0.88 for 1‐year mortality), calibration, overall performance, and decision curve analysis.Conclusion: The previously developed ML algorithms demonstrated good performance in the current study, thereby providing external validation. The models were incorporated into an accessible application (https://sorg-apps.shinyapps.io/extremitymetssurvival/) that may be freely utilized by clinicians in helping predict survival for individual patients and assist in informative decision‐making discussion before operative management of long bone metastatic lesions.


  • Is local recurrence in bone and soft tissue sarcomas just a local recurrence or does it impact the overall survival, retrospective cohort from a sarcoma referral center

    by Obada Hasan, Momin Nasir, Muneeba Jessar, Mustafa Hashimi, Qiang An, Benjamin J. Miller

    Background and Objectives: Sarcoma local recurrence (LR) is often associated with metastasis, but it is unclear if LR can be a causal event leading to metastasis. We question if LR is best viewed as an independent oncologic event or as a worrisome harbinger threatening a patient's overall survival.Methods: We identified patients with LR and/or metastasis from an ongoing cohort of 629 patients with primary sarcoma and performed a detailed review to assess the timing of metastasis resulting in the following groups: (1) Isolated LR, (2) LR before metastasis, (3) LR within 6 months of metastasis, (4) LR 6–12 months after metastasis, (5) LR >12 months after metastasis, and (6) metastasis at diagnosis.Results: Overall, 43 patients met the inclusion criteria with an LR rate of 7%. Ten patients (2% of the entire cohort, 23% of LR) developed an LR before or within 6 months of metastasis. For patients without systemic disease preceding LR, 3 of 23 soft tissue sarcoma STS (13%) and 7 of 10 bone sarcoma (70%) subsequently developed metastasis (p < 0.01).Conclusion: LR with subsequent metastasis is a rare event. LR appears to be best viewed as a marker of tumor aggressiveness rather than the cause of metastasis and poor survival. LR in bone sarcoma patients should warn providers of a high risk of imminent metastasis.


  • What is the likelihood of nonpulmonary metastasis occurring in the absence of lung metastasis in bone and soft tissue sarcoma? A nested case‐control from a sarcoma referral centre

    by Obada Hasan, Momin Nasir, Muneeba Jessar, Mustafa Hashimi, Qiang An, Benjamin J. Miller

    Background and Objectives: Nonpulmonary metastases (NPM) are rare, associated with a poorer prognosis, and maybe missed on conventional chest imaging for sarcoma surveillance. We determined (1) the proportion of NPM occurring in isolation or with synchronous or prior pulmonary metastases (PM), and (2) if initial NPM would have been recognized with a standard surveillance protocol.Methods: Investigators identified patients who developed initial NPM without prior evidence of or concurrent PM from an ongoing cohort of bone and soft tissue sarcoma (STS) patients. Logistic regression at univariate level was done.Results: There were 138/630 (22%) patients with metastasis and 66 (10%) had NPM: 50 (8%) patients had PM presenting first, while 16 (3%) had initial NPM. Malignant peripheral nerve sheath tumor, angiosarcoma, rhabdomyosarcoma, synovial sarcoma, and myxoid liposarcoma were six times more likely to develop initial NPM than other subtypes of STS with odds ratio = 6 (95% confidence interval: 1.93–18.65, p value < 0.01). Chest imaging and physical examination were sufficient to identify NPM in all except three bone sarcoma patients.Conclusions: Patients who develop initial NPM are rare and demonstrate a predilection towards some subtypes of extremity sarcoma. They develop oligometastatic disease, which may be amenable for surgical excision. All isolated or initial NPM in STS patients were discovered by physical examination and standard chest imaging.


  • Open Access

    Google COVID-19 Vaccination Search Insights: Anonymization Process Description

    by Shailesh Bavadekar, Adam Boulanger, John Davis, Damien Desfontaines, Evgeniy Gabrilovich, Krishna Gadepalli, Badih Ghazi, Tague Griffith, Jai Gupta, Chaitanya Kamath, et al.

    This report describes the aggregation and anonymization process applied to the COVID-19 Vaccination Search Insights (published at http://goo.gle/covid19vaccinationinsights), a publicly available dataset showing aggregated and anonymized trends in Google searches related to COVID-19 vaccination. The applied anonymization techniques protect every user's daily search activity related to COVID-19 vaccinations with $(\varepsilon, \delta)$-differential privacy for $\varepsilon = 2.19$ and $\delta = 10^{-5}$.